全文获取类型
收费全文 | 1635篇 |
免费 | 247篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 21篇 |
妇产科学 | 113篇 |
基础医学 | 92篇 |
口腔科学 | 20篇 |
临床医学 | 132篇 |
内科学 | 484篇 |
皮肤病学 | 9篇 |
神经病学 | 15篇 |
特种医学 | 14篇 |
外国民族医学 | 1篇 |
外科学 | 48篇 |
综合类 | 237篇 |
预防医学 | 33篇 |
眼科学 | 11篇 |
药学 | 495篇 |
1篇 | |
中国医学 | 77篇 |
肿瘤学 | 141篇 |
出版年
2024年 | 7篇 |
2023年 | 38篇 |
2022年 | 41篇 |
2021年 | 89篇 |
2020年 | 85篇 |
2019年 | 84篇 |
2018年 | 85篇 |
2017年 | 119篇 |
2016年 | 112篇 |
2015年 | 107篇 |
2014年 | 128篇 |
2013年 | 159篇 |
2012年 | 92篇 |
2011年 | 123篇 |
2010年 | 75篇 |
2009年 | 72篇 |
2008年 | 74篇 |
2007年 | 73篇 |
2006年 | 73篇 |
2005年 | 85篇 |
2004年 | 60篇 |
2003年 | 45篇 |
2002年 | 36篇 |
2001年 | 20篇 |
2000年 | 12篇 |
1999年 | 12篇 |
1998年 | 8篇 |
1997年 | 6篇 |
1996年 | 4篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1991年 | 2篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1982年 | 2篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有1947条查询结果,搜索用时 15 毫秒
21.
目的:验证二甲双胍治疗抗精神病药引起的血脂异常的疗效和安全性。方法:将两项随机、安慰剂的
对照研究纳入分析。共有201例服用抗精神病药物后出现血脂异常的首发精神分裂症患者,并将其分为1 000 mg/d
二甲双胍组(以下简称为二甲双胍组,n=103)和安慰剂组(n=98),观察24周。在基线、治疗后第12周和第24周进行
临床症状及体重、血糖、血脂等代谢指标的评估。结果:二甲双胍治疗后,二甲双胍组和安慰剂组之间低密度脂
蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)的平均差异从基线时的0.16 mmol/L,降低到第24周结束时的
–0.86 mmol/L,降低了1.02 mmol/L,差异有统计学意义(P<0.01)。而24周结束时,二甲双胍组LDL-C≥3.37 mmol/L的
患者有25.3%,显著低于安慰剂组24周结束时的64.8%(P<0.01)。与安慰剂组相比,二甲双胍组的体重、体重指数、
胰岛素、胰岛素抵抗指数、总胆固醇、三酰甘油和高密度脂蛋白胆固醇也有显著变化,差异均有统计学意义(均
P<0.05)。治疗对体重和胰岛素抵抗的影响出现在第12周,并且在第24周进一步改善,但对改善血脂异常的作用在第
24周结束时才出现。结论:二甲双胍治疗对于改善抗精神病药物引起的血脂异常和胰岛素抵抗是有效的,并且改善
抗精神病药物诱导的胰岛素抵抗出现的时间早于降低血脂异常的时间。 相似文献
22.
将2型糖尿病患者共80例分为对照组(n=40)和观察组(n=40),对照组患者给予二甲双胍治疗,观察组患者给予沙格列汀联合二甲双胍治疗。两组患者治疗后空腹及餐后2小时血糖、肿瘤坏死因子-α(TNF-a)水平较治疗前均明显降低(P<0.05),可溶性类肿瘤坏死因子细胞凋亡弱诱导剂(sTWEAK)较治疗前明显升高(P<0.05),且对照组与观察组患者治疗后血糖控制指标及炎症因子间差异有显著性(P<0.05),且观察组患者的糖化血红蛋白达标率更高;两组患者治疗后胰岛素抵抗指数(HOMA-IR)水平均明显降低(P<0.05)而胰岛β细胞功能指数(HOMA-β)明显升高(P<0.05),且与对照组患者相比,观察组患者的上述指标变化更显著(P<0.05)。因此,沙格列汀联合二甲双胍可以纠正新诊断2型糖尿病患者炎症因子水平、改善胰岛β细胞功能,有效控制血糖。 相似文献
23.
24.
25.
26.
27.
Weifeng Tang Helena Engman Yali Zhu Brian Dayton David W. Boulton 《Clinical therapeutics》2019,41(8):1545-1563
PurposeFixed-combination drug products (FCDPs) for patients with type 2 diabetes mellitus (T2DM) may show efficacy comparable to their individual components (ICs) while improving adherence to treatment. This study evaluated the bioequivalence and safety of 2 dapagliflozin/saxagliptin/metformin extended-release (XR) FCDPs relative to their ICs: saxagliptin and dapagliflozin/metformin XR.MethodsThis randomized, open-label, single-dose, single-center crossover study was conducted in 84 healthy subjects aged 18–55 years. The primary objective was to evaluate the fed-state bioequivalence of a dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP and a dapagliflozin 10-mg/saxagliptin 5-mg/metformin 1000-mg XR FCDP relative to the ICs. Secondary objectives included the evaluation of the effect of food on the pharmacokinetic (PK) parameters of saxagliptin, dapagliflozin, and metformin in both FCDPs and characterization of the PK parameters of the active metabolite of saxagliptin, 5-hydroxy saxagliptin, in healthy subjects. PK parameters (AUC0–∞, AUC0–t, and Cmax) were used to assess the bioequivalence of the 2 FCDPs with their ICs. The Cmax and AUC0–t of the study drugs were compared between female and male subjects to assess sex differences in exposure. Safety and tolerability of both FCDPs and ICs were also assessed with adverse events, vital signs (systolic and diastolic blood pressures and pulse rate), 12-lead ECG, physical examinations, and laboratory assessments.FindingsBoth dapagliflozin/saxagliptin/metformin XR FCDPs were bioequivalent to their ICs. For the dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP, the 90% CI for the geometric mean ratio of dapagliflozin Cmax was slightly above the 80%–125% bioequivalence limit, which is unlikely to be clinically relevant. Food delayed the absorption of the study drugs in both FCDPs, which is unlikely to have a clinically relevant impact on efficacy. In both cohorts, exposure was higher in female subjects compared with male subjects, potentially due to the lower body weight of the female subjects. The safety profile and tolerability of the FCDPs were similar to those of their ICs, and no deaths or serious adverse events were reported.ImplicationsThese data support the use of the dapagliflozin/saxagliptin/metformin XR FCDP in patients with T2DM. ClinicalTrials.gov identifier: NCT03169959. 相似文献
28.
Metformin ameliorates the age‐related changes of d‐galactose administration in ovariectomized mice 下载免费PDF全文
Iman Fatemi Sara Heydari Ayat Kaeidi Ali Shamsizadeh Elham Hakimizadeh Amin Khaluoi Mohammad Allahtavakoli 《Fundamental & clinical pharmacology》2018,32(4):392-399
Metformin (Met) has been shown to have pleiotropic effects such as neuroprotective, antioxidant, and anti‐inflammatory properties making that a potential candidate for the treatment of central nervous system (CNS) disorders. This study was designed to investigate the possible effect of Met on the d ‐galactose (d ‐gal)‐induced aging in ovariectomized mice. The female mice underwent bilateral ovariectomy. d ‐gal was administered orally at a dose of 500 mg/kg, and Met was administrated orally at doses of 1 and 10 mg/kg for 6 weeks. Anxiety‐like behavior was evaluated by the elevated plus‐maze. Physical power was assessed by vertical grid holding test and forced swimming capacity test. The brains were assessed for the level of superoxide dismutase (SOD) and brain‐derived neurotrophic factor (BDNF). Ovariectomy caused anxiety and declined the physical power as well as BDNF and SOD levels. d ‐gal administration in ovariectomized mice exacerbated these deleterious effects. Met hampered the anxiety‐like behavior and strengthened the physical power of d ‐gal‐treated ovariectomized mice. Met also increased the SOD and BDNF levels in the brains of d ‐gal‐treated ovariectomized animals. Based on the obtained results, we suggest Met administration as a novel therapeutic approach for the treatment of age‐related conditions in the absence of female sex hormones. 相似文献
29.